Home/Pipeline/Platform-derived candidates

Platform-derived candidates

Neurodegenerative Diseases

Pre-clinicalActive

Key Facts

Indication

Neurodegenerative Diseases

Phase

Pre-clinical

Status

Active

Company

VRG Therapeutics

About VRG Therapeutics

VRG Therapeutics is a private, pre-clinical stage biotech based in Budapest, Hungary, specializing in AI-powered miniprotein drug discovery. The company's core technology platform, comprising ISEP™ and CREATe™, enables the rapid design and optimization of therapeutic peptides with sub-nanomolar affinity and extreme selectivity. While initially targeting neurodegenerative diseases, VRG's versatile platform supports a diverse pipeline and collaborations in cell and gene therapy, positioning it to address high-value, undrugged targets. The company appears to be in a growth phase, securing grants, expanding its team, and initiating an international roadshow.

View full company profile

Therapeutic Areas

Neurodegenerative Diseases Migraine Cell & Gene Therapy

Other Neurodegenerative Diseases Drugs

Drug	Company	Phase	Status
Undisclosed	Modulo Bio	Discovery	Active
PBI-01207	Phoenix Biotechnology	Pre-clinical	Active
Therapeutic Target Discovery Platform	ValtedSeq	Discovery	Active
Undisclosed Neurology Program(s)	Base4	Preclinical	Active
Platform Application for Neurodegenerative Diseases	ALTUCELL	Pre-clinical/Research	Active
OGG1 Activator Program	Luciole Pharmaceuticals	Pre-clinical	Active
Lysosome Biology Program	Talisman Therapeutics	Preclinical	Active
Microglial Health Program	Talisman Therapeutics	Preclinical	Active
HSF1 Activator Program	Sisu Pharma	Pre-clinical	Active
Neurodegenerative Biomarkers R&D	Firalis	Development	Active
Neurodegeneration Pipeline	Origenis	Preclinical	Active
Enhanced Brain Delivery (EBD™) Platform	Acumen Pharmaceuticals	Preclinical	Research Stage